iBio, Inc. - Product Pipeline Review - 2015

Published: Dec, 2015 | Pages: 52 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

iBio, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'iBio, Inc. - Product Pipeline Review - 2015', provides an overview of the iBio, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of iBio, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of iBio, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of iBio, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the iBio, Inc.'s pipeline products

Reasons to Buy

- Evaluate iBio, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of iBio, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the iBio, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of iBio, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of iBio, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of iBio, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
iBio, Inc. Snapshot 6
iBio, Inc. Overview 6
Key Information 6
Key Facts 6
iBio, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
iBio, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
iBio, Inc. - Pipeline Products Glance 15
iBio, Inc. - Clinical Stage Pipeline Products 15
Phase I Products/Combination Treatment Modalities 15
iBio, Inc. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
iBio, Inc. - Drug Profiles 18
anthrax vaccine 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
HAI-05 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
influenza [strain A/H1N1] vaccine 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
malaria vaccine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
NaAPR1M-74 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
agalsidase alfa 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
anthrax + plague vaccine 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
human papillomavirus [Serotype 16] vaccine 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
IBIOCFB-03 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Monoclonal Antibody for Respiratory Anthrax 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Monoclonal Antibody to Inhibit Neuraminidase for Influenza 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
palivizumab biosimilar 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
plague vaccine 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Recombinant Protein to Replace Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
rituximab biosimilar 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
yellow fever vaccine 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
influenza [strain H7N9] vaccine 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Recombinant Protein for Oncology 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
trypanosomes vaccine 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
iBio, Inc. - Pipeline Analysis 40
iBio, Inc. - Pipeline Products by Target 40
iBio, Inc. - Pipeline Products by Route of Administration 41
iBio, Inc. - Pipeline Products by Molecule Type 42
iBio, Inc. - Pipeline Products by Mechanism of Action 43
iBio, Inc. - Recent Pipeline Updates 44
iBio, Inc. - Dormant Projects 49
iBio, Inc. - Locations And Subsidiaries 50
Head Office 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 51
Disclaimer 52

List of Tables

iBio, Inc., Key Information 6
iBio, Inc., Key Facts 6
iBio, Inc. - Pipeline by Indication, 2015 8
iBio, Inc. - Pipeline by Stage of Development, 2015 10
iBio, Inc. - Monotherapy Products in Pipeline, 2015 11
iBio, Inc. - Combination Treatment Modalities in Pipeline, 2015 12
iBio, Inc. - Partnered Products in Pipeline, 2015 13
iBio, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 14
iBio, Inc. - Phase I, 2015 15
iBio, Inc. - Preclinical, 2015 16
iBio, Inc. - Discovery, 2015 17
iBio, Inc. - Pipeline by Target, 2015 40
iBio, Inc. - Pipeline by Route of Administration, 2015 41
iBio, Inc. - Pipeline by Molecule Type, 2015 42
iBio, Inc. - Pipeline Products by Mechanism of Action, 2015 43
iBio, Inc. - Recent Pipeline Updates, 2015 44
iBio, Inc. - Dormant Developmental Projects,2015 49